Attorney Docket No. Le A 36 293

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Yalkinoglu, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/008879

Title: Biomarkers for Diagnosing Alzheimer's Disease

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed *before* the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No.: 48,972
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516

Telephone: (203) 812-6450 Facsimile: (203) 812-6459

pt dat	e: 0	2/2:	3/20	105	_		٠			DT15	Resid PCT/	PTO 2	3 FEB	2005		
Form PTO (Modified)	rm PTO-1449 U.S. Dent of Commerce odified) Patent Trademark Office					ce æ	Serial No.	Art Unit	Filing	Date J D	7 52	5 NS 3				
								- 1	[To Be Assigned Applicant(s)	11			Le A 30	293		
INFORMATION DISCLOSURE CITATION							TION									
								$oldsymbol{ol}}}}}}}}}}}}}}}}}}$	Yalkinoglu, et al.							
							U.	S. PA	TENT DOCU							
•		DOCUMENT NO.						_	DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE			
		_	<u> </u>													
						Г	Г									
								\top			1					
	 	\vdash	 	_		\vdash	\vdash	+-			+		 			
	 	-	 	_	1	 	\vdash	\vdash	1		+		-			
	\vdash	\vdash	-	 	 	⊢	├	₩			+					
	├—			—	<u> </u>	ــ	┞	ــــ								
				\perp	'											
							FORE	EIGN	PATENT DO							
٠		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION YES NO			
/D.B./	F1	0	0	2	5	1	3	8	04/05/00	wo		 	1123	110		
	F2	0	1	6	3	2	9	4	30/08/01	wo						
/D.B.	-	⊢	-	-	<u> </u>	<u> </u>	Ŀ	 						-		
		<u> </u>		<u> </u>	<u></u> —'	<u> </u>	<u> </u>	1			لـــــــــا					
	L		$oxed{oxed}$													
				Γ.	Γ'	Γ '	Γ	Γ_								
		_				H	t	<u> </u>	T . 1				-	_		
			—								1	·				
		1 337-1	OTH	ER R	EFEF	RENC	ES (Inclu	ding Author, T	itle, Date, Per	tinent Pages	, etc.)				
D.B./	R1	(11):	Wei, et al., "Cystatin C: Icelandic-Like Mutation in an Animal Model of Cerebrovascular β -Amyloidosis," <i>Stroke</i> , <u>27</u> (11): 2080-2085 (1996).													
/D.B./	R2	Utal, et al., "Preliminary Expression Analysis in Alzheimer's Disease Using SELDI Protein Chips," Society for Neuroscience Abstracts, 26.(1-2). Abstract No. 83.7, 30 th Annual Meeting of the Society of Neuroscience, New Orleans, LA, USA.														
/D.B./	R3	Prote Data	einChi abase A	ip® Te Accessi	chnolo ion No	ogy," <i>L</i> o. PRE	Databa V 2003	ase Bio 300358	ghly Specific Test cosis Online, Bioso 8956, Abstract and al Biology: Transla	ciences Informati d Faseb Journal,	ion Service, Ph , Vol. 17, No. 4	hiladelphia, I 1-5, March 2	PA, March 2003, Abstr	ract		
						.g 0	<u> </u>		- Diology, Transit	ang the oction	e, our Diego,	C11, 0011, 11	ipin 11-15	,, 2003.		

EXAMINER DATE CONSIDERED *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.